Advocacy intelligence hub — real-time data for patient organizations
Peking University First Hospital — PHASE2
Peking University Third Hospital — PHASE2
Tianjin Medical University Second Hospital — NA
Samsung Medical Center
Tyra Biosciences, Inc — PHASE2
Zealand University Hospital — NA
Samsung Medical Center — PHASE2
Changhai Hospital — PHASE2
University of Michigan Rogel Cancer Center — PHASE2
Tianjin Medical University Second Hospital — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Renacidin Irrigation
United-Guardian, Inc.
Patient Assistance Programs1
Jelmyto
UroGen Pharma, Ltd.
Jelmyto
(mitomycin)Orphan drugUroGen Pharma, Ltd.
12.1 Mechanism of Action Mitomycin inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree ...
Renacidin Irrigation
(Citric acid, glucono-delta-lactone and magnesium carbonate)Orphan drugUnited-Guardian, Inc.
OPDIVO
(NIVOLUMAB)standardE.R. Squibb & Sons, L.L.C.
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytoki...
Hailong Hu, PhD
Tianjin Medical University Second Hospital
Joyce Baard, MD, MSc
AmsterdamUMC
Jonathan Coleman, MD
Memorial Sloan Kettering Cancer Center
Matthew D Galsky
City of Hope Comprehensive Cancer Center
📍 Duarte, California
Solomon Woldu, MD, M.D
UT Southwestern Medical Center at Dallas
📍 DALLAS, TX
Derrick McKinley, MD
UroGen Pharma